Table 3.
Period | Documented Infection | Symptomatic Disease |
---|---|---|
14–34 days after the first dose | 97.7% (95.4–99.0%) | 99.2% (96.4–99.8%) |
14–41 days after the second dose | 94.8% (87.0–97.8%) | 97.2% (90.3–99.2%) |
42–69 days after the second dose | 83.0% (65.0–92.0%) | 85.0% (63.0–94.2%) |
>69 days after the second dose | 81.0% (42.0–94.0%) | 88.0% (42.0–97.6%) |